BET-Inhibitor, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, FEDRATINIB
CA011-023
Phase 2 small_molecule active
Quick answer
BET-Inhibitor, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, FEDRATINIB for DIPSS-Intermediate or High Risk Myelofibrosis is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- DIPSS-Intermediate or High Risk Myelofibrosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active